Home » Stocks » LEGN

Legend Biotech Corporation (LEGN)

Stock Price: $31.45 USD 1.00 (3.28%)
Updated December 3, 4:00 PM EST - Market closed

Stock Price Chart

Key Info

Market Cap 579.47M
Revenue (ttm) 57.26M
Net Income (ttm) -132.97M
Shares Out 258.70M
EPS (ttm) -1.32
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 3
Last Price $31.45
Previous Close $30.45
Change ($) 1.00
Change (%) 3.28%
Day's Open 31.00
Day's Range 31.00 - 31.97
Day's Volume 345,903
52-Week Range 25.80 - 42.56

More Stats

Market Cap 579.47M
Enterprise Value 426.40M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 258.70M
Float n/a
EPS (basic) -1.32
EPS (diluted) -1.32
FCF / Share -0.89
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.18M
Short Ratio 4.83
Short % of Float n/a
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 10.12
PB Ratio 11.59
Revenue 57.26M
Operating Income -137.05M
Net Income -132.97M
Free Cash Flow -115.00M
Net Cash 153.07M
Net Cash / Share 8.31
Gross Margin 105.21%
Operating Margin -239.33%
Profit Margin -232.20%
FCF Margin -200.82%
ROA n/a
ROE n/a
ROIC -368.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (3)

Buy 3
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(61.11% upside)
Current: $31.45
Target: 50.67
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth16.55%-
Gross Profit57.2649.13
Operating Income-137-15.43
Net Income-133-2.78
Shares Outstanding259259
Earnings Per Share-1.32-0.02
Operating Cash Flow-76.43306
Capital Expenditures-38.56-20.94
Free Cash Flow-115285
Cash & Equivalents159216
Total Debt6.114.32
Net Cash / Debt153212
Book Value-1238.65
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Legend Biotech Corporation
Employees 800

Stock Information

Ticker Symbol LEGN
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: LEGN
IPO Date June 5, 2020


Legend Biotech Corporation, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel cell therapies for oncology and other indications. Its lead product candidate, LCAR-B38M/JNJ-4528, is an autologous CAR-T cell therapy that targets the B-cell maturation antigen. The company is conducting multiple clinical trials to evaluate LCAR-B38M/JNJ-4528 as an earlier line of therapy for multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in Revlimid-refractory MM. It also has a broad portfolio of earlier-stage autologous product candidates targeting various cancers, including non-hodgkins lymphoma (NHL), acute myeloid leukemia, and T cell lymphoma. In addition, the company is developing an allogeneic CAR-T product candidate targeting CD20 for the treatment of NHL, which is currently in an investigator-initiated Phase 1 clinical trial in China. Further, it has various product candidates in early preclinical and clinical development for the treatment of solid tumors, as well as infectious diseases. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.